Literature DB >> 26389154

Response.

Chiara Cremolini, Fotios Loupakis, Heinz-Josef Lenz.   

Abstract

Mesh：

Year:  2015        PMID： 26389154      PMCID： PMC4836811          DOI： 10.1093/jnci/djv205

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Authors:  D Klingbiel; Z Saridaki; A D Roth; F T Bosman; M Delorenzi; S Tejpar
Journal:  Ann Oncol       Date:  2014-10-30       Impact factor: 32.976

2.  Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data.

Authors:  Jennifer M Weiss; Patrick R Pfau; Erin S O'Connor; Jonathan King; Noelle LoConte; Gregory Kennedy; Maureen A Smith
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

3.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

Authors:  Gordon Hutchins; Katie Southward; Kelly Handley; Laura Magill; Claire Beaumont; Jens Stahlschmidt; Susan Richman; Philip Chambers; Matthew Seymour; David Kerr; Richard Gray; Philip Quirke
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

4.  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

Authors:  J Goldstein; B Tran; J Ensor; P Gibbs; H L Wong; S F Wong; E Vilar; J Tie; R Broaddus; S Kopetz; J Desai; M J Overman
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

5.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Authors:  Susan D Richman; Matthew T Seymour; Philip Chambers; Faye Elliott; Catherine L Daly; Angela M Meade; Graham Taylor; Jennifer H Barrett; Philip Quirke
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Is there a difference in survival between right- versus left-sided colon cancers?

Authors:  Robert A Meguid; Mark B Slidell; Christopher L Wolfgang; David C Chang; Nita Ahuja
Journal:  Ann Surg Oncol       Date:  2008-07-12       Impact factor: 5.344

8.  Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.

Authors:  Arnaud D Roth; Mauro Delorenzi; Sabine Tejpar; Pu Yan; Dirk Klingbiel; Roberto Fiocca; Giovanni d'Ario; Laura Cisar; Roberto Labianca; David Cunningham; Bernard Nordlinger; Fred Bosman; Eric Van Cutsem
Journal:  J Natl Cancer Inst       Date:  2012-10-25       Impact factor: 13.506

9.  Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Authors:  Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman
Journal:  Clin Cancer Res       Date:  2014-08-19       Impact factor: 12.531

10.  Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes.

Authors:  Kari Hemminki; Irene Santi; Marianne Weires; Hauke Thomsen; Jan Sundquist; Justo Lorenzo Bermejo
Journal:  BMC Cancer       Date:  2010-12-21       Impact factor: 4.430
View more
  2 in total

1.  Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.

Authors:  Takuro Mizukami; Masaki Takahashi; Yu Sunakawa; Satoshi Yuki; Yoshinori Kagawa; Atsuo Takashima; Kyoko Kato; Hiroki Hara; Tadamichi Denda; Yoshiyuki Yamamoto; Manabu Shiozawa; Eiji Oki; Wataru Okamoto; Takayuki Yoshino; Takako Eguchi Nakajima
Journal:  Target Oncol       Date:  2022-05-07       Impact factor: 4.493

2.  Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease.

Authors:  Holger Rumpold; M Hackl; A Petzer; D Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-03       Impact factor: 4.322
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.